Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes

被引：0
|
作者：
Ruotolo, G. [1 ]
Roth, K. D. [1 ]
Milligan, P. L. [1 ]
Lin, Y. [1 ]
Wilson, J. M. [1 ]
Pirro, V [1 ]
Duffin, K. L. [1 ]
Haupt, A. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3056 / 3056
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of once weekly tirzepatide, a dual GIP/GLP-1 receptor agonist versus placebo as monotherapy in people with type 2 diabetes (SURPASS-1)
    Rosenstock, J.
    Wysham, C.
    Frias, J. P.
    Kaneko, S.
    Lee, C. J.
    Lando, L. Fernandez
    Mao, H.
    Cui, X.
    Thieu, V. T.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 246 - 246
  • [42] Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
    Wang, Lijing
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 1547 - 1559
  • [43] Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes
    Mahase, Elisabeth
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2023, 382 : 2074
  • [44] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Michael A. Nauck
    David A. D‘Alessio
    [J]. Cardiovascular Diabetology, 21
  • [45] Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
    Nauck, Michael A.
    D'Alessio, David A.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [46] Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist, on glycemic control and body weight in Japanese patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [47] Effects of the GLP-1 Receptor Agonist on Fatty Liver in Patients With Type 2 Diabetes
    Ogino, Jun
    Yoneda, Chihiro
    Tajima, Kanako
    Ichimura, Yasuhiko
    Fukushima, Sayaka
    Haruki, Takenori
    Sakuma, Yukie
    Iwai, Rie
    Nishino, Takayoshi
    Suzuki, Yoshifumi
    Hashimoto, Naotake
    [J]. DIABETES, 2013, 62 : A256 - A257
  • [48] Design of a novel long-acting dual GLP-1/GIP receptor agonist
    Dong, Yuanzhen
    Zhang, Jinhua
    Xu, Hongjiang
    Shen, Hengqiao
    Lu, Qin
    Feng, Jun
    Cai, Zhengyan
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 100
  • [49] Effect of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Glycemic Control and Body Weight in Japanese Patients with T2DM
    Ohwaki, Kenji
    Furihata, Kenichi
    Mimura, Hanaka
    Oura, Tomonori
    Imaoka, Takeshi
    [J]. DIABETES, 2019, 68
  • [50] Weekly dual GIP/GLP-1 receptor agonist tirzepatide monotherapy improved markers of islet cell function and insulin sensitivity in people with type 2 diabetes (SURPASS-1)
    Lee, C. J.
    Thieu, V. T.
    Mao, H.
    Thomas, M. K.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 245 - 246
12345